The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, ...

Expensive branded nasal sprays cut the length of a cold by ... which could stem the rising problem of antibiotic resistance. 'By 2050, there will be more deaths from antibiotic resistance than ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...